President Donald Trump May 30 signed the “Right to Try” bill into law, making it possible for terminally ill patients to bypass FDA to gain access to experimental drugs.
A group of melanoma experts, joined by three advocacy groups focused on melanoma, has engaged FDA in a public discussion of the challenges of developing new drugs in the refractory setting and the role crossover can play in such trials.
